ESI Group: A More Inclusive and Safer Industry for Women and Everyone Thanks to Simulation
8.3.2023 23:35:00 EET | Business Wire | Press release
Regulatory News:
ESI Group (Paris:ESI) (ISIN Code: FR0004110310, Symbol: ESI) is a global partner in simulation and virtual prototyping software for various industries. The company is committed to promoting gender equality through various actions, including the recruitment of women and their professional development within the industry. In addition, the Group is advocating for a swift change in legislation to allow the use of virtual prototyping in certification tests in the automotive industry, with the ultimate goal of ensuring the safety of all users, irrespective of their gender or body shape.
According to the World Economic Forum, women are 47% more likely than men to be seriously injured in a car accident. The study of the Insurance Institute of Highway Safety (IIHS) published in 2021 underlines that women have a mortality rate 20 to 28% higher than men during a road accident, a situation explained in part because of the poor consideration of female morphology in crash tests.
Florence Barré, Women@ESI General Delegate and Chief of Staff to Cristel de Rouvray, CEO of ESI Group: " The role of digitization in ensuring highway safety cannot be overstated. By incorporating diverse morphologies in simulations, virtual prototyping can better protect the entire population. Although the automotive industry has widely adopted virtual prototyping, the use of virtual human models that account for a wide range of morphologies remains optional. Therefore, legislators must take an active role in encouraging the systematic adoption of these practices to ensure optimal safety for all users, regardless of their gender or body shape."
Crash tests that no longer correspond to the reality of society
The current system that we have inherited today has remained relatively unchanged for the past 50 years. Mandatory physical tests in the automotive industry no longer reflect the reality of modern society. Shockingly, only one out of the five dummy models used in crash tests until recently was designed to represent female physiology. This particular model, created in the late 1980s, was based on just 5% of the female population and was mostly used in the front and rear passenger positions, with very little consideration for the driver's seat in regulatory test scenarios.
Towards a major breakthrough?
In a significant milestone for both technological advancement and industry awareness, a team of Swedish engineers announced the creation of the world's first female crash test dummy late last year. This achievement highlights the increasing importance of gender inclusion and equality, which are rapidly gaining traction worldwide. However, the question remains: how can we ensure that this breakthrough is accessible and available to all?
The use of digital human models
ESI Group firmly believes that regulatory evolution is necessary to encourage the adoption of agile and inclusive methods, rather than relying solely on physical tests and prototypes as reference tools for passive safety certifications. Moving towards a more virtual and diverse approach enables the representation of current driving practices, including various morphotypes and passenger positions.
Virtual prototyping allows for flexible parameter modifications and facilitates testing on all morphotypes, enabling even more comprehensive results. Additionally, simulation can incorporate morphological diversity in a faster and less expensive manner. Many of ESI Group's industrial partners are already utilizing virtual prototyping to address this challenge. In fact, ESI Group was the first to perform a virtual crash test on the Volkswagen Polo back in 1985, allowing major automotive OEMs to conduct virtual testing of their prototypes instead of costly and time-consuming physical tests.
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1000 people around the world and reported 2022 sales of €130 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005777/en/
Contact information
ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28
Aline Besselièvre
aline.besselievre@gmail.com
+33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
